<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Surgery</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7D76EBCF-EC19-4D94-8F9A-891E96618C12"><gtr:id>7D76EBCF-EC19-4D94-8F9A-891E96618C12</gtr:id><gtr:firstName>Shonit</gtr:firstName><gtr:surname>Punwani</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/12AEA4CF-1EE5-420B-AEFD-E8D7DF219FC0"><gtr:id>12AEA4CF-1EE5-420B-AEFD-E8D7DF219FC0</gtr:id><gtr:firstName>Xavier</gtr:firstName><gtr:surname>Golay</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D95FD8DB-7962-41E1-9432-6CB0BFCA1193"><gtr:id>D95FD8DB-7962-41E1-9432-6CB0BFCA1193</gtr:id><gtr:firstName>Charles</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Swanton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BF0FA04E-A61B-44AE-8B61-F730DD602DDF"><gtr:id>BF0FA04E-A61B-44AE-8B61-F730DD602DDF</gtr:id><gtr:firstName>Viviane</gtr:firstName><gtr:otherNames>Julie, Renee, Emilie</gtr:otherNames><gtr:surname>Devauges</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6C7126D7-BCFE-4C1F-BEC9-3D8EB43744AE"><gtr:id>6C7126D7-BCFE-4C1F-BEC9-3D8EB43744AE</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Geoffrey</gtr:otherNames><gtr:surname>Gadian</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1304D061-A5C0-4394-AB3A-68D2D61C08D5"><gtr:id>1304D061-A5C0-4394-AB3A-68D2D61C08D5</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Hawkes</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F8789207-6C68-42DA-AE00-383DA81503C5"><gtr:id>F8789207-6C68-42DA-AE00-383DA81503C5</gtr:id><gtr:firstName>Tony Tsz-Cheong</gtr:firstName><gtr:surname>Ng</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/858B8F93-1BC9-463A-B4ED-9EBD7CCB801D"><gtr:id>858B8F93-1BC9-463A-B4ED-9EBD7CCB801D</gtr:id><gtr:firstName>Ivan</gtr:firstName><gtr:otherNames>Tarasovych</gtr:otherNames><gtr:surname>Gout</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/969661EE-B38C-4950-B7AF-EAD0DE4190E8"><gtr:id>969661EE-B38C-4950-B7AF-EAD0DE4190E8</gtr:id><gtr:firstName>Manuel.</gtr:firstName><gtr:surname>Rodriguez-Justo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C7018E93-1A33-46A1-8A52-B9D6172469A8"><gtr:id>C7018E93-1A33-46A1-8A52-B9D6172469A8</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Lythgoe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/1E39BE6F-4FCC-4626-A04E-DFAD17FCEE7F"><gtr:id>1E39BE6F-4FCC-4626-A04E-DFAD17FCEE7F</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Emberton</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM009092%2F1"><gtr:id>218FF18F-A9E3-434B-9855-A2069B205FE6</gtr:id><gtr:title>Centre for Image Guided Therapy - A Theranostic Approach to Patients with Cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/M009092/1</gtr:grantReference><gtr:abstractText>Our vision is to revolutionise diagnosis, risk stratification and therapy for people with cancer based on innovations in magnetic resonance (MR) technology. The new system of care will be based on developing a strategy of optimized 'target generation', specific 'target verification' and precise 'target destruction'

We use imaging to find out where cancer lies within the body. We call the process of taking an image to find a lesion 'target generation'. Whilst imaging helps to find disease we don't always know whether a lesion on an image is cancer or whether it is benign. Also, if a lesion is cancer we don't often know what that means for the individual patient. By way of explanation, we may know that a particular distribution of cancer spread within the body confers a poorer outcome for a group of patients e.g. a 50% of patients survive after 5-years; however, we often can't tell whether an individual patient will fall into the 50% that survive. Understanding the nature of a lesion detected on imaging and how this impacts on treatment choices and overall treatment outcome is termed 'target verification'.

Our proposal seeks to establish a platform to allow new methods and advances we have been making in pre-clinical 'target generation' to be robustly and rapidly developed for clinical use. It also seeks to develop the best imaging technologies and combine these with an understanding of the cellular and molecular environment of cancers in order to significantly improve 'target verification'. 

The third aspect to our proposal is the development of new technologies to deliver precise treatment to individual cancer sites. We term this 'target destruction'. A range of technologies exist and we aim to provide the environment where the best and most promising of these can be easily translated from conception of idea all the way to clinical application. We have a strong track record in this area with therapies for prostate cancer and we seek to extend this to other cancer sites, initially lung and gastrointestinal cancers. 

Our proposal brings together a group of scientist with complementary skills in imaging, surgery and engineering in one location through establishing a dedicated Centre for Image Guided Therapy within University College London. Within this we seek to establish a translational imaging facility, which will reflect the type of imaging available within the clinical environment, and will also allow scientists access to the cutting-edge equipment to enable them to develop technological advances rapidly and robustly to a stage that they can be applied for patient benefit.</gtr:abstractText><gtr:technicalSummary>Our vision is to revolutionise diagnosis, risk stratification and therapy for people with cancer based on innovations in magnetic resonance (MR) technology; which exploit multi-parametric MR imaging for target generation; employ hyperpolarised magnetic resonance spectroscopy (MRS) for target verification; and where indicated, destroy the 'target' in a selective manner with MR guided and targeted therapies.
Establishing the infrastructure that enables this vision through a clinical translational pipeline is the central strand of our application. As well as overcoming technological barriers, translation also necessitates multi-disciplinary teamwork with free access to both pre-clinical and clinical infrastructure. Establishment of a new UCL centre bringing together basic and clinical scientists to expedite clinical translation of imaging and image guided therapies supports our vision. Our choice of infrastructure develops novel technologies and complements our clinical translational pipeline. We request a clinical grade MRI scanner to provide a translational platform for developments in software, hardware and new target verification and destruction methods. A DNP hyperpolariser pairs with this for exploratory evaluation and clinical translation of hyperpolarized metabolites. We seek to integrate emerging technologies directly into clinic through our newly established UCLH Macmillan Cancer Centre (&amp;pound;100 m), which houses the first and currently only PET-MRI installation within the UK and a 3T MRI research facility. A second DNP hyperpolariser and multi-nuclear MRI coil upgrades for the clinical facilities enables direct linkage with the clinical translational suite. We partner with industry for translation of MR guided intra-urethral HIFU in prostate cancer and novel development of Magnetic Resonance Targeting. Finally we integrate and validate imaging through companion genomics, optical proteomics-based pathway analysis and histopathology (molecular pathology suite).</gtr:technicalSummary><gtr:potentialImpactText>The potential benefits of an integrated pathway where a lesion is imaged, verified and treated based on a MRI platform are self-evident: potentially fewer visits; shorter time to diagnosis; less invasive treatment; less theatre time; reduced radiation hazard; an ambulatory care pathway; less harm and potentially large cost savings over a number of cancer types. In the first instance our target cancer patients with prostate; lung and gastrointestinal cancers will directly benefit from this paradigm.

Our pipeline of novel or enhanced imaging systems emanating from UCL Centres for Medical Image Computing and Advanced Biomedical Imaging will now have a smooth and efficient path to translation. Examples about to make this transition include Gluco-CEST (Walker-Samuel et al. Nature Medicine 2013;19:1067-72); MR Microstructure Imaging (Alexander et al. Neuroimage. 2011 ;56:1301-15); photoacoustics (Zang et al. Phys Med Biol 2009;54:1035-46), all backed by an &amp;pound;8m EPSRC/CRUK KCL/UCL Cancer Imaging Centre (KCL/UCL CIC) and EPSRC Intelligent Imaging (&amp;pound;6m). Delivering these target generation techniques to the clinic has the potential wider benefit to non-cancer areas for example inflammatory (e.g. grading of liver cirrhosis) and cardiovascular (e.g. assessment for ischaemic heart disease). The work would develop new tools for evaluation of disease states.

Our programme of work on target verification will also rapidly benefit patients with our target cancers above. However it has broader applicability to other cancer types as well as non-cancer diseases included neurological and cardiovascular disease. Our approach to work collaboratively as part of a UK initiative on hyperpolariser technology development and translation will ensure that advances made at UCL and at other Universities are shared and developed for the widest impact.

Our group has led on several global initiatives to both harmonise and improve conduct and reporting of MRI-based detection methods for prostate ccer (Dickinson L et al. J Magn Reson Imaging. 2013;37:48-58. Dickinson L et al. Eur Urol. 2011;59:477-94). We have, in addition, introduced standards for the procurement of tissue when using an MRI-guided sampling technique - standards that are now being universally adopted (Moore C et al. Eur Urol. 2013;64:544-52). It is into this infrastructure that we wish to introduce the other, more experimental, elements of the theranostic pathway, namely - target verification and target destruction. Our work has helped shape the 2014 National Institute of Clinical Excellence guidelines on the management of prostate cancer. We expect our work to continue to inform national guidelines. Our aim is to expand application beyond prostate cancer to our other index cancers: lung and gastrointestinal where we expect application of image guided therapy to be of interest to national and international patient management pathways.

The potential for UK invention and for UK industry to exploit our theranostic pathway, again, is considerable. The majority of our industrial partnerships are with non-UK based entities. This reflects well on our international standing and our ability to exploit the attributes of the NHS and the UK funding streams. However, we recognise the need for a healthy and vibrant UK commercial sector in healthcare. Our theranostic pathway is already creating IP within nationally funded but commercially oriented projects (Magnatherm HTA i4i, Ahmed &amp;pound;1.3m; Smart-Target Wellcome/DoH Health innovation Challenge Fund, Emberton &amp;pound;2.3m). Magnetic Resonance Targeting has the potential to create a completely new class of therapy that is non-invasive, multi-organ and delivered in an ambulatory setting. UK industry (such as Tesla) have a unique opportunity to be in on the first wave of development and implementation.</gtr:potentialImpactText><gtr:fund><gtr:end>2016-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5286740</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>MRI Hyperpolariser collaboration</gtr:description><gtr:id>9D242DE8-6431-4445-9A20-E903F59EC7DE</gtr:id><gtr:impact>Joint grant applications. Shared protocols. Broadening of expertise</gtr:impact><gtr:outcomeId>56e0118fea9410.95188846-1</gtr:outcomeId><gtr:partnerContribution>Know how and expertise</gtr:partnerContribution><gtr:piContribution>A collaboration with the team at Cambridge through Shonit Punwani (UCL) has been established. A grant has been submitted to CRUK with Punwani as lead.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>World wide media coverage</gtr:description><gtr:form>A broadcast e.g. TV/radio/film/podcast (other than news/press)</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BCC876D0-5F89-4C58-914F-594BA601940E</gtr:id><gtr:impact>PROMIS (Lancet 2017) was picked up by radio 4 Today programme and 135 other news outlets followed including Reuters, CNN and BBC world. Altimetrics is scoring 1080 a month after publication.</gtr:impact><gtr:outcomeId>58b19f5ac8d6b1.39970801</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Our research has transformed the diagnostic pathway</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6B7E3137-D706-43D9-95AB-8FDD0FF31878</gtr:id><gtr:impact>The diagnostic test that we have developed is 100% more accurate than the existing practice standard.</gtr:impact><gtr:outcomeId>58b1a0396b31e3.39793649</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.bbc.co.uk/news/health-38665618</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>23B26BCB-0218-4D1D-A2EE-A5611355BB7B</gtr:id><gtr:title>Why Focal Therapy is a Legitimate and Necessary Response to a Changing World.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cfd1bcca0.41529861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F0A8F745-9C66-4844-A4BC-58FB03182C9C</gtr:id><gtr:title>The Effect of Dutasteride on Magnetic Resonance Imaging Defined Prostate Cancer: MAPPED-A Randomized, Placebo Controlled, Double-Blind Clinical Trial.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0953d8a49279c0166f606bce7c66b82"><gtr:id>c0953d8a49279c0166f606bce7c66b82</gtr:id><gtr:otherNames>Moore CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cf73e7033.81286777</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98BF8B2D-D0BA-4641-97FD-35A75833EA48</gtr:id><gtr:title>Will the attributes of multiparametric MRI permit the creation of a new approach to therapy?</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c0953d8a49279c0166f606bce7c66b82"><gtr:id>c0953d8a49279c0166f606bce7c66b82</gtr:id><gtr:otherNames>Moore CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>58395cfbe33989.16258540</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>390188C9-A1E5-462B-ABDA-A069F2B7AD16</gtr:id><gtr:title>Visually directed vs. software-based targeted biopsy compared to transperineal template mapping biopsy in the detection of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>58395cfcc30b91.69268314</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AD96595-829A-446E-83EA-D085BBC5CABD</gtr:id><gtr:title>Prostate-specific antigen vs. magnetic resonance imaging parameters for assessing oncological outcomes after high intensity-focused ultrasound focal therapy for localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Urologic oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1078-1439</gtr:issn><gtr:outcomeId>58395cf79dc675.14546336</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBCA1A95-5B2B-4D5A-953D-60E52C5E440F</gtr:id><gtr:title>The FORECAST study - Focal recurrent assessment and salvage treatment for radiorecurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>58395cfcefd5a3.40291689</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB0AEE84-1CF1-45AA-B672-56707C665D50</gtr:id><gtr:title>Histological outcomes after focal high-intensity focused ultrasound and cryotherapy.</gtr:title><gtr:parentPublicationTitle>World journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0724-4983</gtr:issn><gtr:outcomeId>58395cfda5d868.78734667</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D082165-2D2B-4438-B18C-0FD1EF4FCEB0</gtr:id><gtr:title>Focal Therapy of Prostate Cancer Using Irreversible Electroporation.</gtr:title><gtr:parentPublicationTitle>Techniques in vascular and interventional radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1557-9808</gtr:issn><gtr:outcomeId>565f0037b9d616.52488187</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F9E09AE3-D3B2-491E-B4C7-3373557952AB</gtr:id><gtr:title>PROMIS--Prostate MR imaging study: A paired validating cohort study evaluating the role of multi-parametric MRI in men with clinical suspicion of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Contemporary clinical trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1551-7144</gtr:issn><gtr:outcomeId>56e82362bb9c65.83327748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2D46155-5EFF-4055-A5E0-A04BFDEE68A3</gtr:id><gtr:title>Development and internal validation of a multivariable prediction model for biochemical failure after whole-gland salvage iodine-125 prostate brachytherapy for recurrent prostate cancer.</gtr:title><gtr:parentPublicationTitle>Brachytherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a447763738280388783e60c367254aa"><gtr:id>3a447763738280388783e60c367254aa</gtr:id><gtr:otherNames>Peters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1538-4721</gtr:issn><gtr:outcomeId>58395cf9f122f4.07542467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B650D6CA-06D0-447B-857D-760038601CE0</gtr:id><gtr:title>Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8162342ee017c7fa8a0a5fb4646e0e0"><gtr:id>f8162342ee017c7fa8a0a5fb4646e0e0</gtr:id><gtr:otherNames>Taneja SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cf92ec648.42930413</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1373D2B5-F50C-436D-8EAB-3E959677600F</gtr:id><gtr:title>Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants.</gtr:title><gtr:parentPublicationTitle>Nuclear medicine communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ded67235e4b1f2e87e50805699e080"><gtr:id>28ded67235e4b1f2e87e50805699e080</gtr:id><gtr:otherNames>Haroon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0143-3636</gtr:issn><gtr:outcomeId>58395cfc4a0b85.25973664</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DFAAFD16-213C-40F4-817A-7E89DB591ECF</gtr:id><gtr:title>Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0ee0f357a0e2776fd8425a5ea7834596"><gtr:id>0ee0f357a0e2776fd8425a5ea7834596</gtr:id><gtr:otherNames>Saunders EJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>58395cf99efde3.60740693</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>19E9303F-AC47-4536-B2F2-9A2E8F7EF360</gtr:id><gtr:title>&amp;quot;Textural analysis of multiparametric MRI detects transition zone prostate cancer&amp;quot;.</gtr:title><gtr:parentPublicationTitle>European radiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9c2a439a092c7f1c14e4d1e537110f"><gtr:id>1a9c2a439a092c7f1c14e4d1e537110f</gtr:id><gtr:otherNames>Sidhu HS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0938-7994</gtr:issn><gtr:outcomeId>58395cf7bf3491.31460184</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>497B7A48-2650-4DA5-8730-1367661E2859</gtr:id><gtr:title>Transperineal template prostate-mapping biopsies: an evaluation of different protocols in the detection of clinically significant prostate cancer.</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58395cfc6651e5.54837474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>42A9E054-7873-48E3-BE7A-DEA5EF6C2C63</gtr:id><gtr:title>The next level of 3D tumour models: immunocompetence.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4ae62560c7f47dd9a0d1fe50275d9dc"><gtr:id>d4ae62560c7f47dd9a0d1fe50275d9dc</gtr:id><gtr:otherNames>Nyga A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>58395cf980b6f7.95719856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D0F13891-83DF-4D61-8B52-FDA5AF34D828</gtr:id><gtr:title>Population-based prediction of subject-specific prostate deformation for MR-to-ultrasound image registration.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>58395cfb288cc3.85852638</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D139346-50F9-42E8-B69C-8D5E1311571C</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58395cf86a3485.13916257</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DE6889B8-1094-420B-B87E-B8359EBEE57D</gtr:id><gtr:title>Evolution of multi-parametric MRI quantitative parameters following transrectal ultrasound-guided biopsy of the prostate.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/073af5e226e1db72679eaaf562ff0ccd"><gtr:id>073af5e226e1db72679eaaf562ff0ccd</gtr:id><gtr:otherNames>Latifoltojar A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58395cfca6fa50.62979125</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17099DB8-00BB-4E04-AE91-906EC23E277D</gtr:id><gtr:title>From computer-assisted intervention research to clinical impact: The need for a holistic approach.</gtr:title><gtr:parentPublicationTitle>Medical image analysis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8144309476f16b779b4ffae21286af93"><gtr:id>8144309476f16b779b4ffae21286af93</gtr:id><gtr:otherNames>Ourselin S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1361-8415</gtr:issn><gtr:outcomeId>58395cf8a327c0.57993512</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>335D7A21-A517-4B49-9AE6-AD144883BBB7</gtr:id><gtr:title>Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/800f1b5e80bd1464791dcfafe175fff9"><gtr:id>800f1b5e80bd1464791dcfafe175fff9</gtr:id><gtr:otherNames>Ahmed HU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58b19cea0a79a3.50954611</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1E629063-BC97-49E7-835B-02B12C91B04B</gtr:id><gtr:title>Is a negative prostate biopsy a risk factor for a prostate cancer related death?</gtr:title><gtr:parentPublicationTitle>The Lancet. Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1470-2045</gtr:issn><gtr:outcomeId>58aea78a9b35a7.10537917</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9CD3B5DB-A9C6-4109-B6EF-C4AAF6251746</gtr:id><gtr:title>Editorial Comment.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d98c29beb6dc28d0f861418f49d65494"><gtr:id>d98c29beb6dc28d0f861418f49d65494</gtr:id><gtr:otherNames>Ahmed H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cf9554a28.53563175</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B8CC64C-6696-461A-8053-36737483CB69</gtr:id><gtr:title>Re: Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study: J. E. Thompson, D. Moses, R. Shnier, P. Brenner, W. Delprado, L. Ponsky, M. Pulbrook, M. B&amp;ouml;hm, A.-M. Haynes, A. Hayen and P. D. Stricker J Urol 2014;192:67-74.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>548456debca047.01702642</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>349C792F-2369-48F4-A466-2D199AB7C384</gtr:id><gtr:title>Medium-term Outcomes after Whole-gland High-intensity Focused Ultrasound for the Treatment of Nonmetastatic Prostate Cancer from a Multicentre Registry Cohort.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0c97efd9e846f66e37e723bed51b279e"><gtr:id>0c97efd9e846f66e37e723bed51b279e</gtr:id><gtr:otherNames>Dickinson L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58395cf9cb13f4.27239165</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>912F858F-71F5-4237-9B7A-9CCE23469ADC</gtr:id><gtr:title>Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe5e9c2c85f1431b1dc66f938326d3eb"><gtr:id>fe5e9c2c85f1431b1dc66f938326d3eb</gtr:id><gtr:otherNames>Donaldson IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>548456de3b2f64.83511253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A119E176-7328-459E-9C84-2359E34E3FDC</gtr:id><gtr:title>Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>548456dee727d4.44213663</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AB504FB2-9CD4-4A50-818B-D0643E82E55F</gtr:id><gtr:title>Doubling our precision of risk stratification in early prostate cancer: too good to be true?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58395cfaaab6f2.06671250</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABED2D76-F39D-4EE3-857D-034430F5269C</gtr:id><gtr:title>Does true Gleason pattern 3 merit its cancer descriptor?</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/134fb593404f7c02f3c80ae47154f1db"><gtr:id>134fb593404f7c02f3c80ae47154f1db</gtr:id><gtr:otherNames>Miah S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>58395cf840ba00.50150818</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9664350C-8559-4CB9-85D1-9F22E6C11EE4</gtr:id><gtr:title>A review of economic evaluations of diagnostic strategies using imaging in men at risk of prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6454855c445b6fbb286e933cb83c3172"><gtr:id>6454855c445b6fbb286e933cb83c3172</gtr:id><gtr:otherNames>Willis SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>58395cfc308695.79432206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BB275C79-699E-45EC-A8C5-22E36214684E</gtr:id><gtr:title>Dosimetry Modeling for Focal Low-Dose-Rate Prostate Brachytherapy.</gtr:title><gtr:parentPublicationTitle>International journal of radiation oncology, biology, physics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e33068cb3fc39fd3a7d2badb577eaa0e"><gtr:id>e33068cb3fc39fd3a7d2badb577eaa0e</gtr:id><gtr:otherNames>Al-Qaisieh B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0360-3016</gtr:issn><gtr:outcomeId>58395cfdc6d5b1.13295447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1DFA91A0-1B7A-48AF-86B6-EA0D46A86A5B</gtr:id><gtr:title>New and Established Technology in Focal Ablation of the Prostate: A Systematic Review.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58395cf80e91b1.59747724</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6923D0D1-BB1A-4ABD-AF3A-356E48C8DA9C</gtr:id><gtr:title>F-FECH PET/CT to Assess Clinically Significant Disease in Prostate Cancer: Correlation With Maximum and Total Cancer Core Length Obtained via MRI-Guided Template Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>AJR. American journal of roentgenology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/28ded67235e4b1f2e87e50805699e080"><gtr:id>28ded67235e4b1f2e87e50805699e080</gtr:id><gtr:otherNames>Haroon A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0361-803X</gtr:issn><gtr:outcomeId>58395cf7e23713.65260211</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5A474BF-5980-4F24-BAD0-8700BB4C4E2C</gtr:id><gtr:title>The University College London/Medical Research Council/National Institute of Health Research-Health Technology Assessment PROMIS Trial: An Update.</gtr:title><gtr:parentPublicationTitle>European urology focus</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2405-4569</gtr:issn><gtr:outcomeId>58395cfa49c130.80048092</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>501A3682-1BD7-45B4-A062-44CDA6B645FF</gtr:id><gtr:title>MRI/TRUS fusion software-based targeted biopsy: the new standard of care?</gtr:title><gtr:parentPublicationTitle>Minerva urologica e nefrologica = The Italian journal of urology and nephrology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c56b36796bbf025b599ef2696f821f47"><gtr:id>c56b36796bbf025b599ef2696f821f47</gtr:id><gtr:otherNames>Manfredi M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0393-2249</gtr:issn><gtr:outcomeId>58395cfd84d065.20263915</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2AE2613-C2B8-4B10-B46D-0695508220E8</gtr:id><gtr:title>The challenging landscape of medical device approval in localized prostate cancer.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1759-4812</gtr:issn><gtr:outcomeId>58395cfac43659.37446847</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B2DFA0E-5BAB-47B6-810A-90C9AE8C0035</gtr:id><gtr:title>Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.</gtr:title><gtr:parentPublicationTitle>Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3a447763738280388783e60c367254aa"><gtr:id>3a447763738280388783e60c367254aa</gtr:id><gtr:otherNames>Peters M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0167-8140</gtr:issn><gtr:outcomeId>58395cfa27ed89.45951959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6744DEF9-3866-4ABF-A05A-8018BBF5B368</gtr:id><gtr:title>What Burden of Prostate Cancer Can Radiologists Rule Out on Multiparametric Magnetic Resonance Imaging? A Sensitivity Analysis Based on Varying the Target Condition in Template Prostate Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>Urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7838478a8b9000e687c4618aab3f7612"><gtr:id>7838478a8b9000e687c4618aab3f7612</gtr:id><gtr:otherNames>Anastasiadis E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0090-4295</gtr:issn><gtr:outcomeId>58395cfc85ab82.82487522</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7CD03C6-0CB1-4B1C-AE5D-2F375D51E39D</gtr:id><gtr:title>Evidence based management of male lower urinary tract symptoms: A contemporary update.</gtr:title><gtr:parentPublicationTitle>International journal of surgery (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff4bae62be7efeeedfdabbacb589902f"><gtr:id>ff4bae62be7efeeedfdabbacb589902f</gtr:id><gtr:otherNames>Kasivisvanathan V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1743-9159</gtr:issn><gtr:outcomeId>58395cfae3ec82.80852789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2A03C783-BC2D-468C-A20C-9F8D49AF5094</gtr:id><gtr:title>Methodological considerations in assessing the utility of imaging in early prostate cancer.</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>58395cfc166e55.98446860</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DDA8545-3DBC-499E-A044-0CF9FAA00888</gtr:id><gtr:title>Development and Phantom Validation of a 3-D-Ultrasound-Guided System for Targeting MRI-Visible Lesions During Transrectal Prostate Biopsy.</gtr:title><gtr:parentPublicationTitle>IEEE transactions on bio-medical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/138f33a3f01c841c7c7260f7700fecd5"><gtr:id>138f33a3f01c841c7c7260f7700fecd5</gtr:id><gtr:otherNames>Hu Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0018-9294</gtr:issn><gtr:outcomeId>58395cf8e3dc38.66653207</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>29C5FCE4-092D-4BD4-9636-4269A326D583</gtr:id><gtr:title>INNOVATE: A prospective cohort study combining serum and urinary biomarkers with novel diffusion-weighted magnetic resonance imaging for the prediction and characterization of prostate cancer.</gtr:title><gtr:parentPublicationTitle>BMC cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c6afdb94b8a082f9ac2e93d98bdca44"><gtr:id>9c6afdb94b8a082f9ac2e93d98bdca44</gtr:id><gtr:otherNames>Johnston E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2407</gtr:issn><gtr:outcomeId>58395cf7605346.34107417</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6DFADC8F-0F86-4ADA-BEA0-B8BA9494B09C</gtr:id><gtr:title>PSA nadir as a predictive factor for biochemical disease-free survival and overall survival following whole-gland salvage HIFU following radiotherapy failure.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e0e34dd4c5094ccbbc2960302c5937"><gtr:id>e7e0e34dd4c5094ccbbc2960302c5937</gtr:id><gtr:otherNames>Shah TT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58395cf8893d82.26133930</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2975752-B05A-42D7-8C4F-49DA08876791</gtr:id><gtr:title>[Not Available].</gtr:title><gtr:parentPublicationTitle>Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b63257a79f5c394fc5e602c43dd0fe"><gtr:id>e1b63257a79f5c394fc5e602c43dd0fe</gtr:id><gtr:otherNames>Orczyk C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1166-7087</gtr:issn><gtr:outcomeId>58395cfb474bb0.91698206</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31D3D286-4BD3-4F7A-95AD-37CC344321C7</gtr:id><gtr:title>The Prevalence of Clinically Significant Prostate Cancer According to Commonly Used Histological Thresholds in Men Undergoing Template Prostate Mapping Biopsies.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cfb0e3f35.21270733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3DE335C-E4CC-4C3C-BEDD-FDDC7D8148C6</gtr:id><gtr:title>The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.</gtr:title><gtr:parentPublicationTitle>Prostate cancer and prostatic diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/835c15cd686ecda0bf88fbff78fbaf05"><gtr:id>835c15cd686ecda0bf88fbff78fbaf05</gtr:id><gtr:otherNames>El-Shater Bosaily A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1365-7852</gtr:issn><gtr:outcomeId>58395cf8bf0550.74812582</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC616FAF-9392-4243-8629-305BEBAEA182</gtr:id><gtr:title>Are men who are biopsied without prior prostate magnetic resonance imaging getting substandard care?</gtr:title><gtr:parentPublicationTitle>BJU international</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-4096</gtr:issn><gtr:outcomeId>58395cfb6029b1.47234619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3A2FC063-5006-436D-ACC2-469EA3DB2DB6</gtr:id><gtr:title>The changing prostate cancer pathway - new challenges, new pitfalls.</gtr:title><gtr:parentPublicationTitle>The Medico-legal journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f7f5528d35d61b130ceae38446522338"><gtr:id>f7f5528d35d61b130ceae38446522338</gtr:id><gtr:otherNames>Emberton M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0025-8172</gtr:issn><gtr:outcomeId>58aea78ac99037.43445845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59D0332C-61A3-4713-AA3A-163DEE0A6A46</gtr:id><gtr:title>The Effects of Focal Therapy for Prostate Cancer on Sexual Function: A Combined Analysis of Three Prospective Trials.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ad2d3be338e61118503281999024b4"><gtr:id>40ad2d3be338e61118503281999024b4</gtr:id><gtr:otherNames>Yap T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58395cfb8aa6f9.35043223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DCCE4916-C574-4F6C-ADB7-D0E13E45E63F</gtr:id><gtr:title>Transperineal Magnetic Resonance Imaging-targeted Biopsy versus Transperineal Template Prostate Mapping Biopsy in the Detection of Localised Radio-recurrent Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>Clinical oncology (Royal College of Radiologists (Great Britain))</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8f8a2ddcd108d00c2c032748cd5a3dc"><gtr:id>a8f8a2ddcd108d00c2c032748cd5a3dc</gtr:id><gtr:otherNames>Kanthabalan A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0936-6555</gtr:issn><gtr:outcomeId>58395cf90b1619.42076987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64AE1E33-622A-44CA-BF1F-6BC6D1E87BB1</gtr:id><gtr:title>Reply from Authors re: Giorgio Gandaglia, Alberto Briganti, Andrea Salonia, Francesco Montorsi. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough? Eur Urol 2016;69:852-3: Focal Therapy Preserves Erectile Function in Men with Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>European urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/40ad2d3be338e61118503281999024b4"><gtr:id>40ad2d3be338e61118503281999024b4</gtr:id><gtr:otherNames>Yap T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0302-2838</gtr:issn><gtr:outcomeId>58395cfa6508d4.41014055</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80754000-DF4B-4AD3-B7A9-A3203471C1FC</gtr:id><gtr:title>Nanoknife Electroporation Ablation Trial: A Prospective Development Study Investigating Focal Irreversible Electroporation for Localized Prostate Cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57395251555ed94e6c02a0321b8d7df9"><gtr:id>57395251555ed94e6c02a0321b8d7df9</gtr:id><gtr:otherNames>Valerio M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-5347</gtr:issn><gtr:outcomeId>58395cf781c443.31731255</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>15D6F928-6F90-4433-9928-F72C8E3CA133</gtr:id><gtr:title>What tumours should we treat with focal therapy based on risk category, grade, size and location?</gtr:title><gtr:parentPublicationTitle>Current opinion in urology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e1b63257a79f5c394fc5e602c43dd0fe"><gtr:id>e1b63257a79f5c394fc5e602c43dd0fe</gtr:id><gtr:otherNames>Orczyk C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0963-0643</gtr:issn><gtr:outcomeId>58395cfde81de6.53145968</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M009092/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>5191BE6E-A234-4D62-A4F3-B50DBAAE8217</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.5  Resources and infrastructure (detection)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>